Neogen (NEOG) is back in focus after management updated investors on fiscal 2027, highlighting revenue growth, stronger operating performance, higher guidance and a new food safety technology collaboration that could reshape how the business allocates future capital.
At a share price of $11.79, Neogen has given holders a 1-year total shareholder return of 92.02%, even though the stock is down 13.37% on a 1-month share price basis and has a 5-year total shareholder return that has fallen 71.34%.
Compare Neogen’s surge with other potential breakouts in food, health and safety by scanning our hand-picked 21 high quality undiscovered gems that are still flying under most investors radar.
After a 92% one year run and a long term track record that still shows deep losses for holders, does Neogen’s current price still offer enough upside to justify the risk, or has the easy part of the move already passed?
Most Popular Narrative: 16% Undervalued
On the most followed narrative, Neogen’s fair value of $14 sits above the recent $11.79 close. This places the current enthusiasm in the “re-rating with risk” bucket rather than pure speculation.
Operational improvements and automation at the new Petrifilm production facility, alongside targeted actions to reduce inefficiencies in sample collection and inventory management, are expected to drive gross margin and EBITDA margin improvements over the coming quarters as execution stabilizes and overhead absorption rates improve.
See why 5 investors see Neogen as 16% undervalued.
Result: Fair Value of $14 (UNDERVALUED)
Still, the FDA warning over HYCOAT and the related recall, along with integration issues that pressure costs and profitability, could weaken confidence in the Neogen narrative.
Find out about the key risks to this Neogen narrative.
Another View: What Neogen’s Sales Multiple Is Telling You
Neogen may screen as 16% undervalued against a $14 fair value, yet its current P/S of 2.9x looks demanding. That is above both the US Medical Equipment group at 2.6x and a fair ratio estimate of 1.1x, which points to real valuation risk if sentiment cools.
For investors weighing the recent share price surge against these richer sales multiples, it can help to see how the numbers stack up in a cleaner side by side breakdown, and what that gap might mean if the market starts to lean back toward the fair ratio over time. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Feeling conflicted about Neogen after all of that? Act quickly, study the figures yourself, and pressure test the optimistic case by reviewing the 1 key reward.
Looking for more investment ideas beyond Neogen?
If Neogen has sharpened your focus, do not stop there. Use the Simply Wall Street Screener to line up your next potential moves before the crowd catches on.
- Target potential mispricing by scanning a curated 33 high quality undervalued stocks that already combine solid fundamentals with more modest expectations baked into the share price.
- Prioritise resilience by filtering for a list of solid balance sheet and fundamentals (25 results) so you can focus on businesses that carry less financial strain through different market conditions.
- Control risk while still hunting for upside by zeroing in on a 31 resilient stocks with low risk scores that may offer steadier profiles than more volatile alternatives.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com